Cardiotoxicity remains a leading cause of late-stage drug failure and regulatory delay. Human-relevant New Approach Methodologies (NAMs) are transforming cardiac safety assessment by improving prediction of clinical outcomes and reducing reliance on animal testing with in vitro cardiotoxicity assays.
Comprehensive Cardiac Safety Testing
Our cardiac safety assays are delivered on the CellOPTIQ® platform, an in vitro cardiotoxicity model designed to support decision-making across drug discovery and development for safer clinical translation.
Identify cardiovascular liabilities early during hit-to-lead and lead optimisation phases.
Predict proarrhythmic risk using FDA-aligned assays and human cardiomyocyte models.
Understand mechanisms driving cardiac risk for compound optimization and regulatory decisions.
Together, these approaches provide a complete cardiac safety strategy—from early screening to mechanistic understanding and regulatory support using cardiomyocyte in vitro modelling.
What you gain from working with Clyde Biosciences’ team
Access to a team of experts
End-to-end service from assay design to data analysis and submission
Predict cardiotoxicity earlier in development
Reduce late-stage attrition and clinical risk
Generate human-relevant, translational data
Support regulatory submissions (FDA, CiPA)
Replace or reduce reliance on animal models (NAMs)
Cardiovascular toxicity is a major contributor to drug development failure. Making robust and predictive cardiac safety assessment earlier on is essential for successful drug development.
Start Your Cardiac Safety Study Today
Work with our scientists to design a cardiac safety strategy tailored to your compound and development stage.
Speak to a Cardiac Safety Expert Or contact us at info@clydebio.com